IONIS PHARMACEUTICALS INC — Director's Dealing 2018

Jan 10, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2018-01-08

Reporting Person: CROOKE STANLEY T (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-08	Common Stock	M	10000	$14.69	Acquired	48014	Direct
2018-01-08	Common Stock	S	10000	$52.01	Disposed	38014	Direct
2018-01-08	Common Stock	M	1000	$10.82	Acquired	4062	Indirect
2018-01-08	Common Stock	S	1000	$52.01	Disposed	3062	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-08	Employee Stock Option (right to buy)	$14.69	M	10000	Disposed	2020-01-29	Common Stock (10000)	Direct
2018-01-08	Employee Stock Option (right to buy)	$10.82	M	1000	Disposed	2020-01-01	Common Stock (1000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	725391	Indirect

Footnotes

F1: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.67 to $52.35, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F3: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.67 to $52.35, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.